At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,820 enrolled
Drug / intervention
No intervention (this is a retrospective cohort study)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Determine the Incidence of NTRK Fusions in Subjects With Locally Advanced/Unresectable or Metastatic Solid Tumors With NTRK Fusions and Related Treatment Outcomes.
In Brief
An observational study evaluating No intervention (this is a retrospective cohort study) for Metastatic Solid Tumors. Completed, enrolled 3,820 participants across 1 site.
Detailed Summary
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Solid Tumors
CountriesFrance
CollaboratorsBayer
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedJul 2019
Primary CompletionDec 2022
TodayJul 2026
First PostedJul 8, 2019
Enrollment StartDec 23, 2015
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 7.0 years ago
Interventions
No intervention (this is a retrospective cohort study)other
No intervention (this is a retrospective cohort study) aimed at describing tumour samples. No treatment/intervention is being tested.